CD38 and neoplasm: Daratumumab binds the CD38 molecule and mediates tumor cell killing through mechanisms including complement dependent cytotoxicity (CDC), antibody-dependent cellular phagocytosis, antibody-dependent cellular cytotoxicity (ADCC), and direct induction of tumor cell apoptosis (Wang et al., 2018).